Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis

Pain

Volumn 143, Issue 3, 2009, Pages 238-245

  Simon, Lee S ^a   Grierson, Lisa M ^b   Naseer, Zahid ^b   Bookman, Arthur A M ^c   Zev Shainhouse, J ^b  

^a SDG LLC   (United States)

^b Nuvo Research Inc   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Knee pain; NSAID; Osteoarthritis; Topical diclofenac

Indexed keywords

DICLOFENAC; PLACEBO;

ABDOMINAL PAIN; ACCIDENTAL INJURY; ADULT; APPLICATION SITE REACTION; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVITIS; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; HEADACHE; HUMAN; HYPERTENSION; KNEE OSTEOARTHRITIS; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; ODOR; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SIDE EFFECT; TASTE; TREATMENT OUTCOME; VISION;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRALGIA; DICLOFENAC; DIMETHYL SULFOXIDE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG SYNERGISM; DRUG TOXICITY; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; SKIN; TREATMENT OUTCOME;

EID: 67349168176     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.03.008     Document Type: Article

References (57)

1. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., Christy W., Cooke T.D., Greenwald R., Hochberg M., Howell D., Kaplan D., Koopman W., Longley S I.I.I., Mankin H., McShane D.J., Medsger Jr. T., Meenan R., Mikkelsen W., Moskowitz R., Murphy W., Rothschild B., Segal M., Sokoloff L., and Wolfe F. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 29 (1986) 1039-1049
2. Altman R.D., Hochberg M., Murphy Jr. W.A., Wolfe F., and Lequesne M. Atlas of individual radiographic features in osteoarthritis. Osteoarthritis Cartilage 3 Suppl. A (1995) 3-70
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 43 (2000) 1905-1915
4. Antman E.M., Bennett J.S., Daugherty A., Furberg C., Roberts H., and Taubert K.A. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115 (2007) 1634-1642
5. Baer P.A., Thomas L.M., and Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRCTN53366886]. BMC Musculoskelet Disord 6 (2005) 44
6. Banning M. The use of topical diclofenac for pain in osteoarthritis of the knee: a review. Br J Community Nurs 11 (2006) 487-492
7. Banning M. Topical diclofenac: clinical effectiveness and current uses in osteoarthritis of the knee and soft tissue injuries. Expert Opin Pharmacother 9 (2008) 2921-2929
8. Bellamy N., Buchanan W.W., Chalmers A., Ford P.M., Kean W.F., Kragg G.R., Gerecz-Simon E., and Campbell J. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 20 (1993) 999-1004
9. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15 (1988) 1833-1840
10. Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., Altman R., Brandt K., Dougados M., and Lequesne M. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 24 (1997) 799-802
11. Biswal S., Medhi B., and Pandhi P. Longterm efficacy of topical nonsteroidal anti-inflammatory drugs in knee osteoarthritis: metaanalysis of randomized placebo controlled clinical trials. J Rheumatol 33 (2006) 1841-1844
12. Bookman A.A., Williams K.S., and Shainhouse J.Z. Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 171 (2004) 333-338
13. Brobyn R.D. The human toxicology of dimethyl sulfoxide. Ann NY Acad Sci 243 (1975) 497-506
14. Chan A.T., Manson J.E., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Rimm E.B., Willett W.C., and Fuchs C.S. Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
15. Chou R, Helfand M, Peterson K, Dana T, Roberts C. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative Effectiveness Review No. 4 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-02-0024.). Rockville (MD): Agency for Healthcare Research and Quality; September 2006. Available from: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
16. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
17. ® Drug Information for the Health Care Professional. Micromedex, Inc., Englewood, Colorado, 20th ed.; 2000. p. 435 [Table 1].
18. Evans J.M.M., McMahon A.D., McGilchrist M.M., White G., Murray F.E., McDevitt D.G., and MacDonald T.M. Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 311 (1995) 22-26
19. Forman J.P., Rimm E.B., and Curhan G.C. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med 167 (2007) 394-399
20. Forman J.P., Stampfer M.J., and Curhan G.C. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46 (2005) 500-507
21. Galer B.S. All topical NSAIDs are not created equal - understanding topical analgesic drug formulations. Pain 139 (2008) 237-238 10.1016/j.pain.2008.08.009
22. Galer B.S. Topical drugs for the treatment of pain. In: Loeser J.D. (Ed). Bonica's management of pain. 3rd ed. (2001), Lippincott Williams & Wilkins, Philadelphia (PA) 1736-1741
23. Garcia C.A. Ocular toxicology of dimethyl sulfoxide and effects on retinitis pigmentosa. Ann NY Acad Sci 411 (1983) 48-51
24. Gurtovenko A.A., and Anwar J. Modulating the structure and properties of cell membranes: the molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B 111 (2007) 10453-10460
25. Haynes S., and Gemmell H. Topical treatments for osteoarthritis of the knee. Clin Chiropractic 10 (2007) 126-138
26. Hewitt P.G., Poblete N., Wester R.C., Maibach H.I., and Shainhouse J.Z. In vitro cutaneous disposition of a topical diclofenac lotion in human skin: effect of a multi-dose regimen. Pharmacol Res 15 (1998) 988-992
27. Heyneman C.A., Lawless-Liday C., and Wall G.C. Oral versus topical NSAIDs in rheumatic diseases. A comparison. Drugs 60 (2000) 555-574
28. Hippisley-Cox J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 331 (2005) 1310-1316
29. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., Moskowitz R.W., and Schnitzer T.J. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1541-1546
30. Hui X., Hewitt P.G., Poblete N., Maibach H.I., Shainhouse J.Z., and Wester R.C. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res 15 (1998) 1589-1595
31. ICH Harmonised Tripartite Guideline. E9: Statistical Principles for Clinical Trials. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva, Switzerland, 1998. Available from: http://www.ich.org/UrlGrpServer.jser?@_ID=276&@_TEMPLATE=254.
32. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
33. Lin J., Zhang W., Jones A., and Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 329 (2004) 324-326
34. Mamdani M., Juurlink D.N., Kopp A., Naglie G., Austin P.C., and Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ 328 (2004) 1415-1416 [Epub 2004 May 11]
35. Marzulli F.N., and Maibach H.I. Contact allergy: predictive testing in humans. In: Marzulli F.N., and Maibach H.I. (Eds). Dermatotoxicology and pharmacology. Advances in modern toxicology (1977), Hemisphere Publishing, Washington (DC) 353-372
36. Mason L., Moore R.A., Edwards J.E., Derry S., and McQuay H.J. Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 5 (2004) 28
37. Moore R.A., Derry S., and McQuay H.J. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 8 (2007) 73
38. Moore R.A., Derry S., and McQuay H.J. Topical agents in the treatment of rheumatic pain. Rheum Dis Clin N Am 34 (2008) 415-432
39. National Collaborating Centre for Chronic Conditions. Osteoarthritis: National clinical guideline for care and management in adults. London: Royal College Physicians; 2008. Available from: http://www.nice.org.uk/nicemedia/pdf/CG059FullGuideline.pdf.
40. Nishihata T., Kotera K., Nakano Y., and Yamamazaki M. Rat percutaneous transport of diclofenac and influence of hydrogenated soya lecitin. Chem Pharm Bull 35 (1987) 3807-3812
41. Ozguney I. An alternative topical treatment of osteoarthritis of the knee with cutaneous diclofenac solution. Expert Opin Pharmacother 9 (2008) 1805-1816
42. Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., Wolfe F., Gibofsky A., Simon L., Zlotnick S., and Fort J.G. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63 (2004) 931-939
43. Roth S.H., and Shainhouse J.Z. Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 164 (2004) 2017-2023
44. Rubin L.F. Toxicologic update of dimethyl sulphoxide. Ann NY Acad Sci 411 (1983) 6-10
45. Shainhouse J.Z. OARSI guidelines for hip and knee OA: deciphering the topical drug mélange. Osteoarthritis Cartilage 16 (2008) 1586-1587
46. Shirley H.H., Lundergan M.K., Williams H.J., and Spruance S.L. Lack of ocular changes with dimethyl sulfoxide therapy of scleroderma. Pharmacotherapy 9 (1989) 165-168
47. Tannenbaum H., Bombardier C., Davis P., and Russell A.S. An evidenced-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 33 (2006) 140-157
48. ® therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 33 (2006) 567-573
49. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006 (1). 10.1002/14651858.CD004257.pub2 [Art. No. CD004257].
50. ®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 31 (2004) 2002-2012
51. U.S. Food and Drug Administration. COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. Springfield (VA): National Technical Information Service, U.S. Department of Commerce; 1995.
52. Watkins P.B., Kaplowitz N., and Slattery J.T. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 296 (2006) 87-93
53. Williams A.C., and Barry B.W. Penetration enhancers. Adv Drug Deliv Rev 56 (2004) 603-618
54. Yocum D., Fleischmann R., Dalgin P., Caldwell J., Hall D., and Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis. Arch Int Med 160 (2000) 2947-2954
55. Zacher J., Altman R., Bellamy N., Brühlmann P., Da Silva J., Huskisson E., and Taylor R.S. Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin 24 (2008) 925-950 10.1185/030079908X273066
56. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zienstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., and Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis. Part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15 (2007) 981-1000
57. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., Bierma-Zienstra S., Brandt K.D., Croft P., Doherty M., Dougados M., Hochberg M., Hunter D.J., Kwoh K., Lohmander L.S., and Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis. Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 16 (2008) 137-162